Deerfield's ‘pie house,' nationally known for its unusual wedge shape, sells for $350,000
The 1,122-square-foot pie house, which sits on an oddly shaped, 0.09-acre lot at the corner of Chestnut Street and Hazel Avenue, has drawn national attention — including from 'The Tonight Show's' Jimmy Fallon — for its oblong shape and layout, which were born out of necessity given its small lot size for Deerfield. Built in 2003 and initially met with complaints from area residents, the home has one wall that is just three feet wide and just one bedroom upstairs. There's another bedroom in the pie house's basement.
Over the years, however, the house has become accepted in the area — if not outright embraced — for its uniqueness. What's more, the home now has resold multiple times, and its $350,000 sale price in October comfortably topped its 2021 sale price of $295,000.
The house has 2-1/2 baths, nine-foot ceilings, two hall closets, hardwood floors, a kitchen with new stainless steel appliances, a new refrigerator and microwave, a paver brick walkway and a storage shed. The home lacks a garage but does have a parking pad that can hold up to four cars.
Listing agent Ted Pickus did not respond to a request for comment, and the buyer's agent, Beth Wexler, also did not respond to a request for comment. The house first had been listed in September and found a buyer in just two days.
The home previously had sold for $300,000 in 2004, $284,500 in 2007, $260,000 in 2020, and $295,000 in 2021.
The house had an $8,014 property tax bill in the 2023 tax year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
04-08-2025
- Yahoo
Are Wall Street Analysts Bullish on Baxter International Stock?
Valued at a market cap of $11.3 billion, Baxter International Inc. (BAX) is a global healthcare and medtech company headquartered in Deerfield, Illinois. It specializes in medical products and pharmaceuticals focused on intravenous (IV) therapy, surgical care, anesthesia, drug compounding, and connected healthcare systems. Shares of BAX have lagged behind the broader market over the past 52 weeks. BAX has fallen 39% over this time frame, while the broader S&P 500 Index ($SPX) has gained 14.5%. Moreover, Baxter International stock has dipped 24.7% on a YTD basis, trailing SPX's 6.1% upstick. More News from Barchart Find Winning Momentum Trades With This Moving Average Stock Screener Tariffs, Earnings and Other Can't Miss Items this Week This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Looking closer, the medical products maker has also struggled to keep up with the Health Care Select Sector SPDR Fund's (XLV) 13.3% drop over the past 52 weeks and 4.7% plunge in 2025. On Jul. 31, Baxter posted its second-quarter earnings, and its shares dipped 22.4% as the company lowered its full-year guidance, projecting EPS of $2.42–$2.52, citing ongoing operational headwinds and cautious hospital spending. It reported revenue of $2.81 billion, up 4% year-over-year and in line with guidance, while adjusted EPS rose 28% to $0.59. For the current fiscal year, ending in December 2025, analysts expect BAX's EPS to grow 31.8% year-over-year to $2.49. The company's earnings surprise history is mixed. It beat the consensus estimates in three of the last four quarters, while missing on one occasion. Among the 15 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on four 'Strong Buy' ratings, ten 'Holds,' and one 'Moderate Sell.' This configuration is less bullish than a month ago, with five 'Strong Buy' ratings on the stock. On August 1, Wells Fargo & Company (WFC) analyst Larry Biegelsen maintained an "Equal-Weight" rating on Baxter International but sharply cut the price target from $33 to $24, a 27.3% reduction, reflecting a more cautious outlook on the stock. BAX's mean price target of $36.21 implies a 64.9% from the current market prices. The Street-high price target of $42 implies a robust potential upside of 91.3% from the current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
31-07-2025
- Yahoo
Is Wall Street Bullish or Bearish on Walgreens Boots Alliance Stock?
Walgreens Boots Alliance, Inc. (WBA), headquartered in Deerfield, Illinois, operates as a healthcare, pharmacy, and retail company. Valued at $10.1 billion by market cap, the company offers a wide variety of prescription and non-prescription drugs, as well as primary and acute care, wellness, pharmacy, and disease management services, and health and fitness. Invest in Gold Thor Metals Group: Best Overall Gold IRA Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase American Hartford Gold: #1 Precious Metals Dealer in the Nation Shares of this retail pharmacy giant have underperformed the broader market over the past year. WBA has declined 4.4% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 17%. However, in 2025, WBA stock is up 24.7%, surpassing the SPX's 8.2% rise on a YTD basis. More News from Barchart Morgan Stanley Says Nvidia Has 'Exceptional' Strength. Should You Buy NVDA Stock Here? Dear MicroStrategy Stock Fans, Mark Your Calendars for July 31 2 Growth Stocks Wall Street Predicts Will Soar 74% to 159% Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Zooming in further, WBA's outperformance is also apparent compared to the Health Care Select Sector SPDR Fund (XLV). The exchange-traded fund has declined about 10.7% over the past year. Moreover, WBA's double-digit gains on a YTD basis outshine the ETF's 2.5% dip over the same time frame. On Jun. 26, WBA shares closed up marginally after reporting its Q3 results. Its adjusted EPS of $0.38 surpassed Wall Street's expectations of $0.34. The company's revenue was $39 billion, beating Wall Street forecasts of $36.6 billion. For the current fiscal year, ending in August, analysts expect WBA's EPS to decline 41% to $1.70 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 13 analysts covering WBA stock, the consensus is a 'Hold.' That's based on one 'Strong Buy' rating, 11 'Holds,' and one 'Moderate Sell.' The configuration has been consistent over the past three months. On Jun. 26, Evercore ISI analyst Elizabeth Anderson CFA reiterated a 'Hold' rating on WBA with a price target of $11.45. While WBA currently trades above its mean price target of $11.54, the Street-high price target of $15 suggests a 29% upside potential. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Boston Globe
07-07-2025
- Boston Globe
Former ambassador to Ireland and state rep Claire Cronin joins UMass Amherst
Cronin, a former lawyer, will be a scholar-in-residence for public policy and global affairs working with chancellor Javier Reyes on the university's global education initiatives and international student services. She will also help with its professional development programs, particularly with a focus on law and justice, and will give occasional lectures at the Newton campus. Advertisement While ambassador, two of Cronin's big priorities were convincing Irish companies to invest in the US, and increasing the visits from J-1 visa holders for summer work. Cronin said Ireland currently ranks sixth among all countries in foreign direct investment in the US, up from ninth when she started. (Massachusetts, she said, was one of three states that Irish companies were most interested in, along with California and New Jersey.) And she said the US experienced a record number of J-1 visa holders coming from Ireland for summer work and travel, a fact she attributed in part to the 'Open Doors' program she launched with her staff to encourage young Irish adults to visit the Deerfield Residence in Dublin, the US ambassador's official home in Ireland; more than 5,000 students visited Deerfield over her three years there. Advertisement While working as ambassador, Cronin said she learned about the full extent of UMass Amherst's global partnership program, which involves schools in 30 other countries, including Ireland. She stepped down from the ambassador's role on the day President Trump was sworn in in January, and has spent much of the time since catching up with colleagues and friends. Six months may have passed, but she still sounds like she misses her time on the Emerald Isle. 'I was embraced by the Irish government,' Cronin said. 'They considered me one of their own. ... I may have left Ireland [but] my heart is still there.' This is an installment of our weekly Bold Types column about the movers and shakers on Boston's business scene. Jon Chesto can be reached at
